↓ Skip to main content
What is this page? Embed badge

A Phase I First-in-Human Study of Nesvacumab (REGN910), a Fully Human Anti–Angiopoietin-2 (Ang2) Monoclonal Antibody, in Patients with Advanced Solid Tumors

Overview of attention for article published in Clinical Cancer Research, March 2016
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • Good Attention Score compared to outputs of the same age (75th percentile)
  • Good Attention Score compared to outputs of the same age and source (69th percentile)

Mentioned by

twitter
2 X users
patent
2 patents

Citations

dimensions_citation
51 Dimensions

Readers on

mendeley
55 Mendeley
Summary X Patents Dimensions citations
So far, Dimensions has found 51 publications that cite this research output.

51

The most recent citing publications are shown below. View all 51 publications that cite this research output on Dimensions.

This page shows the most recent citations of this research output.

Click here to find out how to access more activity.

This page is provided by Altmetric.